文献速递淋巴瘤

年轻晚期侵袭性B细胞淋巴瘤患者的放疗:R-MegaCHOEP三期试验长期结果

Radiotherapy in younger patients with advanced aggressive B-cell lymphoma-long-term results from the phase 3 R-MegaCHOEP trial.
PubMed 文献 · Leukemia · 2024-03-27

R-MegaCHOEP三期试验分析261例≤60岁高危侵袭性B细胞淋巴瘤患者,其中120例接受巩固放疗。肿块型病变接受放疗者10年EFS、PFS、OS显著优于未放疗者,继发恶性肿瘤无显著增加;作者认为肿块型病变免疫化疗后巩固放疗应作为一线治疗的一部分。

要点

  • 261例中120例接受放疗,最常见部位为纵隔(50例)和腹主动脉旁(27例)。
  • 中位放疗剂量36 Gy,中位分次1.8 Gy;3级和4级急性毒性分别24例和8例。
  • 肿块型病变放疗者10年EFS 64% vs 35%(P<0.001),PFS 68% vs 47%(P=0.003),OS 72% vs 59%(P=0.011)。

核心结论

  • 肿块型病变免疫化疗后巩固放疗改善年轻高危侵袭性B细胞淋巴瘤患者预后,作者认为应作为一线治疗的一部分。

研究设计与样本

  • R-MegaCHOEP三期试验,比较高剂量化疗联合利妥昔单抗后自体干细胞移植与常规免疫化疗(R-CHOEP)用于≤60岁高危患者,方案包括对肿块型(最大直径≥7.5 cm)或结外病变行放疗,共分析261例,其中120例接受放疗。

主要发现

  • 最常见放疗部位为纵隔(50例)和腹主动脉旁(27例);中位放疗剂量36 Gy,中位分次1.8 Gy。
  • 放疗期间急性毒性多为轻至中度,仅报告24例3级和8例4级毒性。
  • 肿块型病变接受放疗者10年EFS 64% vs 未放疗者35%(P<0.001),PFS 68% vs 47%(P=0.003),OS 72% vs 59%(P=0.011)。
  • 使用放疗未显著增加继发恶性肿瘤。

关键数值与推荐

  • 放疗适应证:肿块型(最大直径≥7.5 cm)或结外病变。
  • 中位放疗剂量36 Gy,中位分次1.8 Gy。
  • 肿块型病变放疗者10年EFS 64% vs 35%(P<0.001),PFS 68% vs 47%(P=0.003),OS 72% vs 59%(P=0.011)。

临床怎么用

  • 作者认为肿块型病变免疫化疗后巩固放疗应作为一线治疗的一部分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The role of consolidative radiotherapy (RT) for patients with aggressive B-cell lymphoma has not been fully elucidated. The R-MegaCHOEP trial investigated the use of high-dose chemotherapy and rituximab with subsequent autologous stem cell transplantations compared to conventional immunochemotherapy (R-CHOEP) for high-risk patients up to 60 years. The study protocol included RT for patients with bulky (maximum diameter ≥7.5 cm) or extranodal disease. Two-hundred sixty-one patients were analyzed, 120 of whom underwent RT. The most frequently irradiated regions were mediastinum (n = 50) and paraaortic (n = 27). Median RT dose was 36 Gray in median fractions of 1.8 Gray. Acute toxicities were mostly mild to moderate, with only 24 and 8 grade 3 and 4 toxicities reported during RT. Patients with bulky disease who received RT showed significantly better 10-year EFS, PFS and OS (EFS: 64% vs. 35%; p < 0.001; PFS 68% vs. 47%; p = 0.003; OS: 72% vs. 59%; p = 0.011). There was no significant increase in secondary malignancies with the use of RT. RT administered for consolidation of bulky disease after immunochemotherapy improved the prognosis of young high-risk patients with aggressive B-cell lymphoma and should be considered part of first-line therapy. The trial was registered with ClinicalTrials.gov, number NCT00129090.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Oertel M, Ziepert M, Frontzek F, et al. Radiotherapy in younger patients with advanced aggressive B-cell lymphoma-long-term results from the phase 3 R-MegaCHOEP trial. Leukemia. 2024. PMID: 38538861. doi:10.1038/s41375-024-02231-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。